Evidence map›Paper›PMID 39060854›Full record

ArticleJournal of racial and ethnic health disparities2025

Racial Disparities in the Diagnosis and Prognosis of ALS Patients in the United States.

Jaime Raymond, Theresa Nair, Kelly Graham Gwathmey, Theodore Larson, D Kevin Horton, Paul Mehta

Abstract read
In one paragraph

Article in Journal of racial and ethnic health disparities, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jaime RaymondOffice of Analytics and Innovation, Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention, 4770 Buford Hwy, Atlanta, GA, 30341, USA. jraymond@cdc.gov.ORCID 0000-0002-5594-6931
Theresa NairOffice of Analytics and Innovation, Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention, 4770 Buford Hwy, Atlanta, GA, 30341, USA.ORCID 0009-0000-3515-6011
Kelly Graham GwathmeyDepartment of Neurology, Virginia Commonwealth University, Richmond, VA, USA.ORCID 0000-0002-7589-8826
Theodore LarsonOffice of Analytics and Innovation, Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention, 4770 Buford Hwy, Atlanta, GA, 30341, USA.ORCID 0000-0003-4719-4829
D Kevin HortonOffice of Analytics and Innovation, Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention, 4770 Buford Hwy, Atlanta, GA, 30341, USA.ORCID 0000-0001-6214-6687
Paul MehtaOffice of Analytics and Innovation, Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention, 4770 Buford Hwy, Atlanta, GA, 30341, USA.ORCID 0000-0002-0796-8861

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmyotrophic lateral sclerosis (ALS) is a progressive, fatal disease with largely unknown etiology. This study compares racial differences in clinical characteristics of ALS patients enrolled in the National ALS Registry (Registry).

methodsData from ALS patients who completed the Registry's online clinical survey during 2013-2022 were analyzed to determine characteristics such as site of onset, associated symptoms, time of symptom onset to diagnosis, and pharmacological and non-pharmacological interventions for White, Black, and other race patients.

resultsSurveys were completed by 4242 participants. Findings revealed that Black ALS patients were more likely to be diagnosed at a younger age, to have arm or hand initial site of onset, and to experience pneumonia than were White ALS patients. ALS patients of other races were more likely than White ALS patients to be diagnosed at a younger age and to experience twitching. The mean interval between the first sign of weakness and an ALS diagnosis for Black patients was almost 24 months, statistically greater than that of White (p = 0.0374; 16 months) and other race patients (p = 0.0518; 15.8 months). The mean interval between problems with speech until diagnosis was shorter for White patients (6.3 months) than for Black patients (17.7 months) and other race patients (14.8 months). CONCLUSIONS AND RELEVANCE: Registry data shows racial disparities still exist in the diagnosis and clinical characteristics of ALS patients. Increased recruitment of non-White ALS patients and better characterization of symptom onset between races might aid clinicians in diagnosing ALS sooner, leading to earlier therapeutic interventions.

Indexed as

Amyotrophic Lateral SclerosisBlack or African AmericanHealthcare DisparitiesHealth Status DisparitiesWhiteAdultAgedFemaleHumansMaleMiddle AgedPrognosisRegistriesUnited StatesAmyotrophic lateral sclerosisClinical characteristics of ALS patientsMinority populationsRace

Identifiers

PMID39060854
PMCPMC12446088

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.